Stock Analiz

Tango Therapeutics, Inc. (TNGX) financials: revenue, earnings and cash flow

Fiscal 2020–2025 · from SEC filings · data as of November 16, 2026

Summary

Tango Therapeutics’s revenue went from $8M in fiscal 2020 to $62M in fiscal 2025, growth of about 52.1% a year.

Net income in fiscal 2025 was -$102M, a net margin of -162.9%; the best year in this period was 2020 with -$52M.

Free cash flow was -$140M in fiscal 2025 and positive in 1 of the 6 years shown.

The diluted share count rose 264% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2020: $8M20202021: $37M20212022: $25M20222023: $37M20232024: $42M20242025: $62M2025$62M
Net income
2020: -$52M20202021: -$58M20212022: -$108M20222023: -$102M20232024: -$130M20242025: -$102M2025-$102M
Free cash flow
2020: $69M20202021: -$61M20212022: -$117M20222023: -$120M20232024: -$132M20242025: -$140M2025-$140M
EPS (diluted)
2020: $-1.6320202021: $-0.9420212022: $-1.2320222023: $-1.0820232024: $-1.1920242025: $-0.872025$-0.87

Income statement

Fiscal year202520242023202220212020
Revenue$62M$42M$37M$25M$37M$8M
Gross profit——————
Operating income-$111M-$146M-$114M-$111M-$58M-$52M
Net income-$102M-$130M-$102M-$108M-$58M-$52M
EPS (diluted)$-0.87$-1.19$-1.08$-1.23$-0.94$-1.63
R&D$132M$144M$115M$106M$78M$50M
Revenue growth+48.3%+15.2%+46.9%−32.9%+383.8%—

Cash flow

Fiscal year202520242023202220212020
Operating cash flow-$139M-$132M-$118M-$109M-$60M$70M
Capital spending-$1M-$754000-$2M-$8M-$2M-$1M
Free cash flow-$140M-$132M-$120M-$117M-$61M$69M
Dividends paid$0$0$0$0$0$0
Buybacks——————
Stock-based pay$26M$29M$19M$14M$8M$2M

Balance sheet

Fiscal year202520242023202220212020
Cash$343M$258M$337M$366M$485M$190M
Debt$34M$36M$36M$41M$2M$8M
Equity$346M$200M$253M$249M$345M$39M
Total assets$399M$316M$403M$436M$500M$207M
Shares (diluted)116M109M95M88M62M32M

Margins and returns

Fiscal year202520242023202220212020
Gross margin——————
Operating margin-178.4%-346.1%-312.6%-446.8%-157.1%-681.8%
Net margin-162.8%-309.7%-278.5%-435.1%-157.2%-678.8%
FCF margin-224.3%-314.4%-327.2%-469.7%-165.7%900.8%
ROIC-23.2%-48.7%-31.1%-30.2%-13.3%-112.3%
ROE-29.3%-65.3%-40.2%-43.4%-16.9%-134.6%

Frequently asked questions

What is Tango Therapeutics’s annual revenue?

$62M in fiscal 2025.

How much profit does Tango Therapeutics make?

Net income was -$102M in fiscal 2025 (net margin -162.9%).

Is Tango Therapeutics’s revenue growing?

Yes: revenue rose 48.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.